サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：COVID-19治療薬の世界市場- 世界の産業分析、サイズ、シェア、成長、動向、および予測、2022-2031年
市場調査レポート
商品コード
1229630

COVID-19治療薬の世界市場- 世界の産業分析、サイズ、シェア、成長、動向、および予測、2022-2031年

COVID-19 Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 185 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
COVID-19治療薬の世界市場- 世界の産業分析、サイズ、シェア、成長、動向、および予測、2022-2031年
出版日: 2023年01月23日
発行: Transparency Market Research
ページ情報: 英文 185 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、2022年を基準年、2031年を予測年として、2017年から2031年までのCOVID-19治療薬の世界市場の収益を掲載しています。また、2022年から2031年までの世界のCOVID-19治療薬市場の年間複合成長率（CAGR %）を掲載しています。

本レポートは、広範な調査を経て作成されました。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施し、調査作業の大部分を行っています。2次調査では、主要企業の製品資料、年次報告書、プレスリリース、および関連文書を参照し、COVID-19治療薬市場を理解しました。

本レポートは、世界のCOVID-19治療薬市場の競合情勢を掘り下げています。世界のCOVID-19治療薬市場で活動する主要企業が特定され、それぞれの企業が様々な属性の観点から、プロファイルを作成しています。企業概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界のCOVID-19治療薬市場のプレイヤーの属性です。

目次

第1章 序文

  • 市場の定義と範囲
  • 市場セグメンテーション
  • 主な調査目的
  • 調査ハイライト

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：COVID-19治療薬の世界市場

第4章 市場の概要

  • イントロダクション
    • セグメントの定義
  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • COVID-19治療薬の世界市場の分析と予測、2017年～2031年
    • 市場収益予測

第5章 キーインサイト

  • 技術的な進歩
  • パイプラインの解析
  • 地域別/世界別の規制シナリオ
  • COVID-19影響度分析

第6章 COVID-19治療薬の世界市場分析・予測：薬効クラス別

  • イントロダクションと定義
  • 主な発見・発展
  • 市場価値予測：薬剤クラス別、2017年～2031年
    • コルチコステロイド
    • 抗ウイルス剤
    • モノクローナル抗体
    • キナーゼ阻害剤
    • その他（抗炎症剤、回復期血漿、その他）
  • 市場の魅力：薬剤クラス別

第7章 COVID-19治療薬の世界市場分析・予測：投与経路別

  • イントロダクションと定義
  • 主な発見・発展
  • 市場価値予測：投与経路別、2017年～2031年
    • オーラル
    • 非経口
  • 市場魅力度：投与経路別

第8章 COVID-19治療薬の世界市場分析・予測：流通チャネル別

  • イントロダクションと定義
  • 主な発見・発展
  • 市場価値予測：流通チャネル別、2017年～2031年
    • 病院内薬局
    • 小売薬局
    • オンラインファーマシーズ
  • 市場魅力度：流通チャネル別

第9章 COVID-19治療薬の世界市場分析・予測：地域別

  • 主な調査結果
  • 市場価値予測：地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ地域
  • 市場魅力度：国・地域別

第10章 北米のCOVID-19治療薬市場の分析と予測

  • イントロダクション
    • 主な調査結果
  • 市場価値予測：薬剤クラス別、2017年～2031年
    • コルチコステロイド
    • 抗ウイルス剤
    • モノクローナル抗体
    • キナーゼ阻害剤
    • その他（抗炎症剤、回復期血漿、その他）
  • 市場価値予測：投与経路別、2017年～2031年
    • オーラル
    • 非経口
  • 市場価値予測：流通チャネル別、2017年～2031年
    • 病院内薬局
    • 小売薬局
    • オンラインファーマシーズ
  • 市場価値予測：国別、2017年～2031年
    • 米国
    • カナダ
  • 市場の魅力度分析
    • 薬効分類別
    • 投与経路別
    • 流通チャネル別
    • 国別

第11章 欧州COVID-19治療薬市場の分析と予測

  • イントロダクション
    • 主な調査結果
  • 市場価値予測：薬剤クラス別、2017年～2031年
    • コルチコステロイド
    • 抗ウイルス剤
    • モノクローナル抗体
    • キナーゼ阻害剤
    • その他（抗炎症剤、回復期血漿、その他）
  • 市場価値予測：投与経路別、2017年～2031年
    • オーラル
    • 非経口
  • 市場価値予測：流通チャネル別、2017年～2031年
    • 病院内薬局
    • 小売薬局
    • オンラインファーマシーズ
  • 市場価値予測：国別/サブ地域別、2017年～2031年
    • ドイツ
    • U.K.
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 市場の魅力度分析
    • 薬効分類別
    • 投与経路別
    • 流通チャネル別
    • 国・地域別

第12章 アジア太平洋のCOVID-19治療薬市場の分析と予測

  • イントロダクション
    • 主な調査結果
  • 市場価値予測：薬剤クラス別、2017年～2031年
    • コルチコステロイド
    • 抗ウイルス剤
    • モノクローナル抗体
    • キナーゼ阻害剤
    • その他（抗炎症剤、回復期血漿、その他）
  • 市場価値予測：投与経路別、2017年～2031年
    • オーラル
    • 非経口
  • 市場価値予測：流通チャネル別、2017年～2031年
    • 病院内薬局
    • 小売薬局
    • オンラインファーマシーズ
  • 市場価値予測：国別/サブ地域別、2017年～2031年
    • 中国
    • 日本
    • インド
    • オーストラリア・ニュージーランド
    • その他アジア太平洋地域
  • 市場の魅力度分析
    • 薬効分類別
    • 投与経路別
    • 流通チャネル別
    • 国・地域別

第13章 ラテンアメリカのCOVID-19治療薬市場の分析と予測

  • イントロダクション
    • 主な調査結果
  • 市場価値予測：薬剤クラス別、2017年～2031年
    • コルチコステロイド
    • 抗ウイルス剤
    • モノクローナル抗体
    • キナーゼ阻害剤
    • その他（抗炎症剤、回復期血漿、その他）
  • 市場価値予測：投与経路別、2017年～2031年
    • オーラル
    • 非経口
  • 市場価値予測：流通チャネル別、2017年～2031年
    • 病院内薬局
    • 小売薬局
    • オンラインファーマシーズ
  • 市場価値予測：国別/サブ地域別、2017年～2031年
    • ブラジル
    • メキシコ
    • その他ラテンアメリカ地域
  • 市場の魅力度分析
    • 薬効分類別
    • 投与経路別
    • 流通チャネル別
    • 国・地域別

第14章 中東・アフリカ COVID-19治療薬市場の分析と予測

  • イントロダクション
    • 主な調査結果
  • 市場価値予測：薬剤クラス別、2017年～2031年
    • コルチコステロイド
    • 抗ウイルス剤
    • モノクローナル抗体
    • キナーゼ阻害剤
    • その他（抗炎症剤、回復期血漿、その他）
  • 市場価値予測：投与経路別、2017年～2031年
    • オーラル
    • 非経口
  • 市場価値予測：流通チャネル別、2017年～2031年
    • 病院内薬局
    • 小売薬局
    • オンラインファーマシーズ
  • 市場価値予測：国別/サブ地域別、2017年～2031年
    • GCC諸国
    • 南ア
    • その他中東・南アフリカ地域
  • 市場の魅力度分析
    • 薬効分類別
    • 投与経路別
    • 流通チャネル別
    • 国・地域別

第15章 競合情勢

  • 市場競争者-競争マトリックス（階層別、企業規模別）
  • 企業別の市場シェア分析（2021年）
  • 企業プロファイル
    • F. Hoffmann-La Roche Ltd
    • Gilead Sciences, Inc.
    • Eli Lilly and Company
    • Pfizer Inc.
    • Merck & Co., Inc.
    • GSK plc.
    • Celltrion Healthcare Co., Ltd.
    • Sorrento Therapeutics, Inc.
    • AstraZeneca
図表

List of Tables

  • Table 01: Global COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 02: Global COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 03: Global COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel 2017-2031
  • Table 04: Global COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 07: North America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 08: North America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel 2017-2031
  • Table 09: Europe COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017-2031
  • Table 10: Europe COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 11: Europe COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 12: Europe COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel 2017-2031
  • Table 13: Asia Pacific COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 15: Asia Pacific COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 16: Asia Pacific COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel 2017-2031
  • Table 17: Latin America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 19: Latin America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 20: Latin America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Middle East & Africa COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 23: Middle East & Africa COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 24: Middle East & Africa COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel 2017-2031

List of Figures

  • Figure 01: Global COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: COVID-19 Therapeutics Market Value Share, by Drug Class, 2021
  • Figure 03: COVID-19 Therapeutics Market Value Share, by Route of Administration, 2021
  • Figure 04: COVID-19 Therapeutics Market Value Share, by Distribution Channel, 2021
  • Figure 05: COVID-19 Therapeutics Market Value Share, by Region, 2021
  • Figure 06: Global COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 07: Global COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 08: Global COVID-19 Therapeutics Market Value (US$ Mn), by Corticosteroids, 2017-2031
  • Figure 09: Global COVID-19 Therapeutics Market Value (US$ Mn), by Anti-viral, 2017-2031
  • Figure 10: Global COVID-19 Therapeutics Market Value (US$ Mn), by Monoclonal Antibodies, 2017-2031
  • Figure 11: Global COVID-19 Therapeutics Market Value (US$ Mn), by Kinase Inhibitors, 2017-2031
  • Figure 12: Global COVID-19 Therapeutics Market Value (US$ Mn), by Others (Anti-inflammatory Drugs, Convalescent Plasma, Others) 2017-2031
  • Figure 13: Global COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 14: Global COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 15: Global COVID-19 Therapeutics Market Value (US$ Mn), by Parenteral, 2017-2031
  • Figure 16: Global COVID-19 Therapeutics Market Value (US$ Mn), by Oral, 2017-2031
  • Figure 17: Global COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel 2021 and 2031
  • Figure 18: Global COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel 2022-2031
  • Figure 19: Global COVID-19 Therapeutics Market Revenue (US$ Mn), by Hospital Pharmacies, 2017-2031
  • Figure 20: Global COVID-19 Therapeutics Market Revenue (US$ Mn), by Retail Pharmacies, 2017-2031
  • Figure 21: Global COVID-19 Therapeutics Market Revenue (US$ Mn), by Online Pharmacies, 2017-2031
  • Figure 22: Global COVID-19 Therapeutics Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 23: Global COVID-19 Therapeutics Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 24: North America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 25: North America COVID-19 Therapeutics Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 26: North America COVID-19 Therapeutics Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 27: North America COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 28: North America COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class 2022-2031
  • Figure 29: North America COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 30: North America COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration 2022-2031
  • Figure 31: North America COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 32: North America COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 33: Europe COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 34: Europe COVID-19 Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 35: Europe COVID-19 Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 36: Europe COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 37: Europe COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 38: Europe COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 39: Europe COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 40: Europe COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 41: Europe COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 42: Asia Pacific COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 43: Asia Pacific COVID-19 Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 44: Asia Pacific COVID-19 Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 45: Asia Pacific COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 46: Asia Pacific COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 47: Asia Pacific COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 48: Asia Pacific COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 49: Asia Pacific COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 50: Asia Pacific COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 51: Latin America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 52: Latin America COVID-19 Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 53: Latin America COVID-19 Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 54: Latin America COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 55: Latin America COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 56: Latin America COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 57: Latin America COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 58: Latin America COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 59: Latin America COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 60: Middle East & Africa COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 61: Middle East & Africa COVID-19 Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 62: Middle East & Africa COVID-19 Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 63: Middle East & Africa COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 64: Middle East & Africa COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 65: Middle East & Africa COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 66: Middle East & Africa COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 67: Middle East & Africa COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 68: Middle East & Africa COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 69: Company Share Analysis
目次
Product Code: TMRGL85370

The report provides revenue of the global COVID-19 therapeutics market for the period 2017-2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global COVID-19 therapeutics market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the COVID-19 therapeutics market.

The report delves into the competitive landscape of the global COVID-19 therapeutics market. Key players operating in the global COVID-19 therapeutics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global COVID-19 therapeutics market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global COVID-19 Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global COVID-19 Therapeutics Market Analysis and Forecasts, 2017 - 2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. Pipeline Analysis
  • 5.3. Regulatory Scenario by Region/globally
  • 5.4. COVID-19 Impact Analysis

6. Global COVID-19 Therapeutics Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017 - 2031
    • 6.3.1. Corticosteroids
    • 6.3.2. Anti-viral
    • 6.3.3. Monoclonal Antibodies
    • 6.3.4. Kinase Inhibitors
    • 6.3.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
  • 6.4. Market Attractiveness, by Drug Class

7. Global COVID-19 Therapeutics Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Attractiveness, by Route of Administration

8. Global COVID-19 Therapeutics Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness, by Distribution Channel

9. Global COVID-19 Therapeutics Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness, by Country/Region

10. North America COVID-19 Therapeutics Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Class, 2017 - 2031
    • 10.2.1. Corticosteroids
    • 10.2.2. Anti-viral
    • 10.2.3. Monoclonal Antibodies
    • 10.2.4. Kinase Inhibitors
    • 10.2.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
  • 10.3. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 10.3.1. Oral
    • 10.3.2. Parenteral
  • 10.4. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2017 - 2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By Route of Administration
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe COVID-19 Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017 - 2031
    • 11.2.1. Corticosteroids
    • 11.2.2. Anti-viral
    • 11.2.3. Monoclonal Antibodies
    • 11.2.4. Kinase Inhibitors
    • 11.2.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
  • 11.3. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 11.3.1. Oral
    • 11.3.2. Parenteral
  • 11.4. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017 - 2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By Route of Administration
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific COVID-19 Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017 - 2031
    • 12.2.1. Corticosteroids
    • 12.2.2. Anti-viral
    • 12.2.3. Monoclonal Antibodies
    • 12.2.4. Kinase Inhibitors
    • 12.2.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
  • 12.3. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 12.3.1. Oral
    • 12.3.2. Parenteral
  • 12.4. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017 - 2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By Route of Administration
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America COVID-19 Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017 - 2031
    • 13.2.1. Corticosteroids
    • 13.2.2. Anti-viral
    • 13.2.3. Monoclonal Antibodies
    • 13.2.4. Kinase Inhibitors
    • 13.2.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
  • 13.3. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 13.3.1. Oral
    • 13.3.2. Parenteral
  • 13.4. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017 - 2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By Route of Administration
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa COVID-19 Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2017 - 2031
    • 14.2.1. Corticosteroids
    • 14.2.2. Anti-viral
    • 14.2.3. Monoclonal Antibodies
    • 14.2.4. Kinase Inhibitors
    • 14.2.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
  • 14.3. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 14.3.1. Oral
    • 14.3.2. Parenteral
  • 14.4. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017 - 2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & South Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Class
    • 14.6.2. By Route of Administration
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 15.2. Market Share Analysis By Company (2021)
  • 15.3. Company Profiles
    • 15.3.1. F. Hoffmann-La Roche Ltd
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. Business Strategies
      • 15.3.1.5. Recent Developments
    • 15.3.2. Gilead Sciences, Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. Business Strategies
      • 15.3.2.5. Recent Developments
    • 15.3.3. Eli Lilly and Company
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. Business Strategies
      • 15.3.3.5. Recent Developments
    • 15.3.4. Pfizer Inc.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. Business Strategies
      • 15.3.4.5. Recent Developments
    • 15.3.5. Merck & Co., Inc.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. Business Strategies
      • 15.3.5.5. Recent Developments
    • 15.3.6. GSK plc.
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. Recent Developments
    • 15.3.7. Celltrion Healthcare Co., Ltd.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. Business Strategies
      • 15.3.7.5. Recent Developments
    • 15.3.8. Sorrento Therapeutics, Inc.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. Business Strategies
      • 15.3.8.5. Recent Developments
    • 15.3.9. AstraZeneca
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. Business Strategies
      • 15.3.9.5. Recent Developments